RxDoctor Payments DataLook up a doctor →

Seung Won Kim, MD

Pain Medicine · Raleigh, NCNPI 1205032984

Payments from drug & device makers

$9,633in general payments, 2019–2025

Across 375 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Forte Bio-pharma LLC$779
  • Collegium Pharmaceutical, Inc.$754
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$541
  • Indivior Inc.$372
  • Medtronic$352
  • plus $4K from 36 others

What the payments were for

  • Speaking & faculty fees$3,00031%
  • Food & beverage$6,63369%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,633 in reported general payments places this provider in the 70th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$113,058
Medicare patients
123
Services billed
1,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucyntaTapentadol Hcl47$60,655
Buprenorphine133$35,015
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl223$32,521
BelbucaBuprenorphine Hcl34$24,418
OxycontinOxycodone Hcl29$18,983
Lidocaine76$15,151
Xtampza ErOxycodone Myristate29$14,563
ZubsolvBuprenorphine Hcl/Naloxone Hcl37$13,147
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen386$12,914
MovantikNaloxegol Oxalate32$12,159
SuboxoneBuprenorphine Hcl/Naloxone Hcl15$8,859
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen210$6,119
Oxycodone Hcl310$4,638
Hysingla ErHydrocodone Bitartrate12$4,403
Pregabalin177$3,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Belbuca, Xtampza Er$754$99,636110 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Buprenorphine Hcl$16$68,149385 claims
Orexo US, Inc.Zubsolv$199$13,14737 claims
Redhill Biopharma Inc.Movantik$48$12,15932 claims
Indivior Inc.Suboxone$372$8,85915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →